Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026MZE782 Phase 1 Healthy Volunteer ...
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
Maze has reached a pivotal moment in our journey. On the heels of a successful IPO and with two ongoing clinical-stage programs – MZE829 for ...
Hosted on MSN3mon
Maze Therapeutics raises $115m to advance kidney disease candidates
Maze Therapeutics has completed a Series D financing ... Deep Track Capital and Frazier Life Sciences co-led the financing round, with Logos Capital and Janus Henderson Investors also taking ...
Hosted on MSN2mon
Maze Therapeutics IPO opens trading modestly higher
Investing.com -- Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced ...
Yahoo Finance2d
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for ...